SANES

10.222

+0.63%↑

BBVA

18.925

+0.64%↑

BNP

87.16

-2.4%↓

CABK

11.025

+0.87%↑

INGA

25.36

+0.14%↑

SANES

10.222

+0.63%↑

BBVA

18.925

+0.64%↑

BNP

87.16

-2.4%↓

CABK

11.025

+0.87%↑

INGA

25.36

+0.14%↑

SANES

10.222

+0.63%↑

BBVA

18.925

+0.64%↑

BNP

87.16

-2.4%↓

CABK

11.025

+0.87%↑

INGA

25.36

+0.14%↑

SANES

10.222

+0.63%↑

BBVA

18.925

+0.64%↑

BNP

87.16

-2.4%↓

CABK

11.025

+0.87%↑

INGA

25.36

+0.14%↑

SANES

10.222

+0.63%↑

BBVA

18.925

+0.64%↑

BNP

87.16

-2.4%↓

CABK

11.025

+0.87%↑

INGA

25.36

+0.14%↑

Kodu・Aktsiate loetelu・Ipsen SA.

Ipsen SA.

Avatud

SektorRahandus

153.7 -7.63

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

151.8

Max

166.4

Põhinäitajad
By Trading Economics
Sissetulek	-225M 110M
Müük	36M 1.9B
P/E Sektori keskmine	30.921 57.736
Dividenditootlus	0.84
Kasumimarginaal	5.899
Töötajad	5,535
EBITDA	-171M 466M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-17.32% downside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.84% 4.52%
Järgmine tulemuste avaldamine	30. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	2.2B 14B
Eelmine avamishind	161.33
Eelmine sulgemishind	153.7

Uudiste sentiment

By Acuity

39%

61%

99 / 438 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

99.85 / 104 Toetus ja vastupanu

Ipsen SA. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. mai 2026, 23:53 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15. mai 2026, 22:47 UTC

Kuumad aktsiad

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. mai 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. mai 2026, 22:00 UTC

Suurimad hinnamuutused turgudel

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. mai 2026, 18:09 UTC

Suurimad hinnamuutused turgudel

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17. mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17. mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17. mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17. mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17. mai 2026, 23:07 UTC

Omandamised, ülevõtmised, äriostud

UOB: Transactions Part of Group's Capital Reallocation Strategy

17. mai 2026, 23:06 UTC

Omandamised, ülevõtmised, äriostud

UOB: Share Sale Agreements Entered With Singland Properties

17. mai 2026, 23:05 UTC

Omandamised, ülevõtmised, äriostud

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Fund Stake Acquisition via Internal Resources

17. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Acquire Stake for $389 Million

17. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16. mai 2026, 16:27 UTC

Omandamised, ülevõtmised, äriostud

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16. mai 2026, 15:26 UTC

Omandamised, ülevõtmised, äriostud

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16. mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. mai 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. mai 2026, 20:19 UTC

Kuumad aktsiad

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. mai 2026, 19:41 UTC

Omandamised, ülevõtmised, äriostud

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. mai 2026, 18:35 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Ipsen SA. Prognoos

Hinnasiht

By TipRanks

-17.32% langus

12 kuu keskmine prognoos

Keskmine 137.25 EUR -17.32%

Kõrge 170 EUR

Madal 117 EUR

Põhineb 4 Wall Streeti analüütiku instrumendi Ipsen SA. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Ipsen SA. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

99.85 / 104Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

99 / 438 Pingereas Rahandus

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.